It’s Time to Think About More. High-Performance Whole Exome Sequencing from Plasma.
Comprehensively profile the tumor, exome-wide Combined with ImmunoID NeXT™, assess tumor heterogeneity, monitor response to therapy, and interrogate mechanisms of resistance
Profile with ImmunoID NeXT, Monitor with NeXT Liquid Biopsy Leverage somatic variant results from the solid tumor, and monitor them for longitudinal analysis, while also detecting de novo mutations as they occur
Discover more: Go beyond typical panel content Exome-wide footprint ensures inclusion of important areas of tumor biology not typically covered in targeted panel approaches to fuel clinical and translational research
Unprecedented performance at exome scale Innovative library preparation, high depth of sequencing, and advanced error suppression techniques deliver results you can trust